Evicenter
Foundayo (orforglipron) in Chronic weight management
Manufacturer
Lilly USA, LLC
Prescribing information
Foundayo (opens in a new tab)
Questions
88
Last updated

All questions

Clinical trials: Foundayo (orforglipron) in chronic weight management

13 questions · 2 sources

Study results

Does Foundayo reduce fat mass more than lean mass?

Note: This passage is from the Pharmacodynamics section of the Prescribing Information. The home page of the Foundayo HCP site describes a body composition (DXA) substudy, but its captured text gives no fat mass or lean mass results.

How much weight did adults without diabetes lose on Foundayo vs placebo (ATTAIN-1)?

Applies to Adults with obesity, or with overweight and at least one weight-related comorbid condition, without type 2 diabetes (ATTAIN-1; Trial 1 in the Prescribing Information)

Note: The values are from the figure description on the clinical data page of the Foundayo HCP site; Table 6 of the Prescribing Information gives the same percent changes with each difference from placebo and its 95% CI.

How much weight did adults with type 2 diabetes lose on Foundayo vs placebo (ATTAIN-2)?

Applies to Adults with obesity or overweight (BMI 27 kg/m2 or greater) and type 2 diabetes (ATTAIN-2; Trial 2 in the Prescribing Information)

Note: The clinical data page of the Foundayo HCP site names the trials ATTAIN-1 and ATTAIN-2, and gives the pooled figures of the label's Trials 1 and 2 under those names (for example, "In a pool of 2 Foundayo clinical studies for weight reduction (ATTAIN-1 and ATTAIN-2), 399 (13%)" patients were 65 or older). The Prescribing Information reports the same enrollment (3,127 and 1,613 adults) under the names Trial 1 and Trial 2. Table 6 of the Prescribing Information gives each difference from placebo with its 95% CI.

What share of patients lost 10% or more of body weight on Foundayo?

“Table 6: Changes from Baseline in Body Weight at Week 72 in Trials 1 and 2 in Patients with Obesity or Overweight with ≥1 Weight-related Comorbid Condition Abbreviations: ANCOVA = analysis of covariance; CI = confidence interval; N = number of patients randomly assigned to trial drug. Note: Baseline mean is calculated using all randomized patients. a The intent-to-treat population consists of all randomized patients. For Trial 1 at Week 72, the body weight endpoint was missing for 24%, 16%, 14%, and 15% of patients randomized to placebo, FOUNDAYO 5.5 mg once daily, 9 mg once daily and 17.2 mg once daily, respectively. For Trial 2 at Week 72, the body weight endpoint was missing for 13%, 13%, 10%, and 7% of patients randomized to placebo, FOUNDAYO 5.5 mg once daily, 9 mg once daily and 17.2 mg once daily, respectively. Missing data were imputed from retrieved patients of the same randomized treatment group when the missingness was possibly related to trial treatment; otherwise, missing data were imputed using observed data from the same randomized treatment group (primary modified multiple imputation). b Unconditional average treatment effect estimated using ANCOVA adjusted for baseline value and other stratification factors. c p<0.001 (unadjusted 2-sided) compared to placebo for superiority; controlled for multiplicity. d Unconditional average treatment effect estimated using logistic regression adjusted for baseline value and other stratification factors. e Not controlled for multiplicity. Trial 1 (without diabetes) Trial 2 (with type 2 diabetes) Intent-to-Treat (ITT) Populationa Placebo once daily N = 949 FOUNDAYO 5.5 mg once daily N = 723 FOUNDAYO 9 mg once daily N = 725 FOUNDAYO 17.2 mg once daily N = 730 Placebo once daily N = 630 FOUNDAYO 5.5 mg once daily N = 329 FOUNDAYO 9 mg once daily N = 332 FOUNDAYO 17.2 mg once daily N = 322 Body Weight Baseline mean (kg) 103.9 103.2 102.2 103.1 101.2 102.3 102.7 99.8 % Change from baselineb -2.1 -7.4 -8.3 -11.1 -2.5 -5.1 -7 -9.6 % difference from placebo (95% CI)b -5.3 (-6.1, -4.4)c -6.2 (-7.1, -5.3)c -9 (-10, -8.1)c -2.6 (-3.5, -1.6)c -4.5 (-5.4, -3.6)c -7.1 (-8.1, -6.1)c % of patients who lost ≥5% body weight 26.8 59.6 63.1 71.5 26.8 47.4 54.7 67 % difference from placebo (95% CI)d 32.7 (27.9, 37.6)c 36.3 (31.5, 41.1)c 44.7 (40, 49.3)c 20.6 (13.9, 27.3)c 27.9 (21.3, 34.5)c 40.2 (33.8, 46.6)c % of patients who lost ≥10% body weight 13 32.5 39.8 54.5 9.2 22.5 31.1 45.6 % difference from placebo (95% CI)d 19.4 (15.1, 23.7)c 26.8 (22.4, 31.1)c 41.4 (37, 45.9)c 13.3 (8.1, 18.5)c 21.9 (16.3, 27.5)c 36.4 (30.5, 42.3)c % of patients who lost ≥15% body weight 6 14.3 20.1 35.9 3.1 6.7 14.4 25.9 % difference from placebo (95% CI)d 8.3 (5.2, 11.4)c 14.1 (10.7, 17.6)c 29.8 (25.9, 33.7)c 3.6 (0.4, 6.8)e 11.3 (7.3, 15.3)c 22.8 (17.8, 27.8)c % of patients who lost ≥20% body weight 2.9 5.9 8.9 18.4 0.7 2.6 4.4 10.8 % difference from placebo (95% CI)d 3 (0.9, 5.2)e 6 (3.5, 8.4)c 15.5 (12.4, 18.6)c 1.8 (-0.2, 3.8)e 3.7 (1.4, 6)e 10.1 (6.6, 13.5)e” (opens the source at this quote in a new tab)

Note: Columns are Trial 1 (without diabetes) placebo, FOUNDAYO 5.5 mg, 9 mg, and 17.2 mg, then Trial 2 (with type 2 diabetes) placebo, FOUNDAYO 5.5 mg, 9 mg, and 17.2 mg, as in the table header. In each "difference from placebo" row the placebo cells are empty. The table also gives the shares of patients who lost at least 5%, 15%, and 20% of body weight. The clinical data page of the Foundayo HCP site names the trials ATTAIN-1 and ATTAIN-2, and gives the pooled figures of the label's Trials 1 and 2 under those names (for example, "In a pool of 2 Foundayo clinical studies for weight reduction (ATTAIN-1 and ATTAIN-2), 399 (13%)" patients were 65 or older). The Prescribing Information reports the same enrollment (3,127 and 1,613 adults) under the names Trial 1 and Trial 2.

Did Foundayo reduce body weight across age, sex, race, and BMI subgroups?

How much does Foundayo reduce waist circumference (ATTAIN-1)?

Applies to Adults with obesity, or with overweight and at least one weight-related comorbid condition, without type 2 diabetes (ATTAIN-1; Trial 1 in the Prescribing Information)

Note: Table 7 of the Prescribing Information gives the same results in centimeters for Trial 1 and Trial 2, with each difference from placebo and its 95% CI.

Does Foundayo lower blood pressure and triglycerides (ATTAIN-1 and ATTAIN-2)?

Note: Columns are Trial 1 (without diabetes) placebo, FOUNDAYO 5.5 mg, 9 mg, and 17.2 mg, then Trial 2 (with type 2 diabetes) placebo, FOUNDAYO 5.5 mg, 9 mg, and 17.2 mg, as in the table header. In each "difference from placebo" row the placebo cells are empty. The Prescribing Information is the governing source. Its Table 7 gives each dose separately for Trial 1 (ATTAIN-1) and Trial 2 (ATTAIN-2) and marks every systolic blood pressure and triglyceride difference from placebo, in both trials, with footnote d, "Not controlled for multiplicity." The clinical data page of the Foundayo HCP site gives pooled results for Foundayo 5.5 mg, 9 mg, and 17.2 mg in ATTAIN-1, cites the ATTAIN-1 publication (Wharton et al., N Engl J Med 2025), and describes triglycerides and systolic blood pressure as controlled for type I error with P<0.001 for superiority of pooled Foundayo. The two sources report different analyses (pooled doses against each dose) and differ on multiplicity control.

How much did Foundayo lower A1C in adults with type 2 diabetes (ATTAIN-2)?

Applies to Adults with obesity or overweight (BMI 27 kg/m2 or greater) and type 2 diabetes (ATTAIN-2; Trial 2 in the Prescribing Information)

Note: Columns are Trial 1 (without diabetes) placebo, FOUNDAYO 5.5 mg, 9 mg, and 17.2 mg, then Trial 2 (with type 2 diabetes) placebo, FOUNDAYO 5.5 mg, 9 mg, and 17.2 mg, as in the table header. In each "difference from placebo" row the placebo cells are empty. The last four columns are Trial 2 (adults with type 2 diabetes). Footnote c marks p<0.001 compared to placebo, controlled for multiplicity; footnote d marks results not controlled for multiplicity. The labeled indication of Foundayo is weight reduction and maintenance.

Clinical trials

What was the Foundayo ATTAIN-1 trial design?

Applies to Adults with obesity, or with overweight and at least one weight-related comorbid condition, without type 2 diabetes (ATTAIN-1; Trial 1 in the Prescribing Information)

Note: The clinical data page of the Foundayo HCP site names the trials ATTAIN-1 and ATTAIN-2, and gives the pooled figures of the label's Trials 1 and 2 under those names (for example, "In a pool of 2 Foundayo clinical studies for weight reduction (ATTAIN-1 and ATTAIN-2), 399 (13%)" patients were 65 or older). The Prescribing Information reports the same enrollment (3,127 and 1,613 adults) under the names Trial 1 and Trial 2.

What was the Foundayo ATTAIN-2 trial design in type 2 diabetes?

Applies to Adults with obesity or overweight (BMI 27 kg/m2 or greater) and type 2 diabetes (ATTAIN-2; Trial 2 in the Prescribing Information)

Note: The clinical data page of the Foundayo HCP site names the trials ATTAIN-1 and ATTAIN-2, and gives the pooled figures of the label's Trials 1 and 2 under those names (for example, "In a pool of 2 Foundayo clinical studies for weight reduction (ATTAIN-1 and ATTAIN-2), 399 (13%)" patients were 65 or older). The Prescribing Information reports the same enrollment (3,127 and 1,613 adults) under the names Trial 1 and Trial 2.

Subgroup results

How much weight did patients with BMI under 35 lose on Foundayo (ATTAIN-1 and ATTAIN-2)?

Note: The third passage gives ATTAIN-2 results as differences from placebo; the figure description gives ATTAIN-1 percent changes for each group.

How much weight did women lose on Foundayo by menopausal stage (ATTAIN-1, post hoc)?

Applies to Adults with obesity, or with overweight and at least one weight-related comorbid condition, without type 2 diabetes (ATTAIN-1; Trial 1 in the Prescribing Information)

“Bar chart shows the percent change in body weight by menopausal stage from baseline to 72 weeks for Foundayo 5.5 mg, 9 mg, and 17.2 mg tablets, and placebo. In the premenopause group for Foundayo 5.5 mg, there were 154 women with a mean baseline weight of 221.6 lb and a 7.4% reduction in body weight from baseline. For Foundayo 9 mg, there were 161 women with a mean baseline weight of 225.1 lb and an 8.3% reduction in body weight from baseline. For Foundayo 17.2 mg, there were 171 women with a mean baseline weight of 219.2 lb and a 12.0% reduction in body weight from baseline. For placebo, there were 225 women with a mean baseline weight of 217.4 lb and a 2.4% reduction in body weight from baseline. In the perimenopause group for Foundayo 5.5 mg, there were 158 women with a mean baseline weight of 214.5 lb and an 8.3% reduction in body weight from baseline. For Foundayo 9 mg, there were 137 women with a mean baseline weight of 210.5 lb and an 10.8% reduction in body weight from baseline. For Foundayo 17.2 mg, there were 142 women with a mean baseline weight of 217.5 lb and a 13.1% reduction in body weight from baseline. For placebo, there were 189 women with a mean baseline weight of 218.9 lb and a 2.3% reduction in body weight from baseline. In the postmenopause group for Foundayo 5.5 mg, there were 154 women with a mean baseline weight of 211.4 lb and an 8.9% reduction in body weight from baseline. For Foundayo 9 mg, there were 168 women with a mean baseline weight of 209.0 lb and a 10.0% reduction in body weight from baseline. For Foundayo 17.2 mg, there were 152 women with a mean baseline weight of 208.6 lb and a 12.6% reduction in body weight from baseline. For placebo, there were 192 women with a mean baseline weight of 211.7 lb and a 1.8% reduction in body weight from baseline.” (opens the source at this quote in a new tab)

On the page, select: Show description

Note: The clinical data page labels this an ATTAIN-1 post-hoc subgroup analysis; the conference presentation it cites (Ciudin et al., ADA 2026) is titled as an analysis from ATTAIN-1 and ATTAIN-2. The page gives no difference from placebo, confidence interval, or p-value.

How much weight did adults 65 and older lose on Foundayo (ATTAIN-1)?

Applies to Adults with obesity, or with overweight and at least one weight-related comorbid condition, without type 2 diabetes (ATTAIN-1; Trial 1 in the Prescribing Information)